Lusutrombopag
- Generic Name
- Lusutrombopag
- Brand Names
- Mulpleta, Mulpleo (previously Lusutrombopag Shionogi)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32Cl2N2O5S
- CAS Number
- 1110766-97-6
- Unique Ingredient Identifier
- 6LL5JFU42F
- Background
Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). TPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well, including erythroid, granul...
- Indication
Lusutrombopag is indicated for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.
- Associated Conditions
- Chronic immune thrombocytopenia
- Associated Therapies
- -
A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06426043
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 215
- Registration Number
- NCT02389621
An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 19
- Registration Number
- NCT01129024
- Locations
- 🇺🇸
Investigator, Seattle, Washington, United States
A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
- Conditions
- Interventions
- First Posted Date
- 2010-01-22
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 20
- Registration Number
- NCT01054443
- Locations
- 🇺🇸
Investigator, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.